1 Min Read
March 17 (Reuters) - Neuren Pharmaceuticals Ltd-
* Requests trading halt pending announcement regarding Neuren’s phase 2 clinical trial of Trofinetide in Rett Syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.